Pritumumab
Product Specifications
UNSPSC Description
Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2].
Target Antigen
Others
Type
Inhibitory Antibodies
Related Pathways
Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/pritumumab.html
Purity
97.77
Solubility
H2O
Smiles
[Pritumumab]
References & Citations
[1]Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. |[2]Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99806/Pritumumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99806/Pritumumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
499212-74-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
TL311867V 500 µL Each
Kallikrein 9 (KLK9) Human shRNA Lentiviral Particle (Locus ID 284366)
Ask
View Details